A Phase 1 Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Vantictumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors OncoMed Pharmaceuticals
- 16 Sep 2016 Status changed to completed.
- 28 Aug 2014 Status changed from suspended to recruiting (US FDA lifts the partial clinical hold).
- 16 Jun 2014 According to an Oncomed media release, the company has voluntarily stopped enrollment and dosing in the phase 1 trials of vantictumab due to the incidence of bone-related adverse events.